We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Software Platform Provides Capabilities for Somatic Variation Analysis

By Michal Siman-Tov
Posted on 22 Nov 2016
Print article
Image: The upgraded Cartagenia Bench Lab 5.0 addresses inherent challenges of interpreting and reporting on genomic variants data (Photo courtesy of Agilent Technologies).
Image: The upgraded Cartagenia Bench Lab 5.0 addresses inherent challenges of interpreting and reporting on genomic variants data (Photo courtesy of Agilent Technologies).
An upgraded information-processing platform enables clinical genetics and molecular pathology laboratories to achieve higher performance and efficiency in somatic variation analysis of tumor-tissue sequencing data and in reporting of tissue-typing results, among other features.

Agilent Technologies (Santa Clara, CA, USA) has released its Cartagenia Bench Lab 5.0, a major new version that addresses inherent challenges of interpreting and reporting on genomic variants data. Cartagenia Bench Lab, registered as an exempt Class I Medical Device in the US, helps high-throughput diagnostic labs to validate and automate their variant assessment and reporting pipelines.

The software enables clinical geneticists and molecular pathologists to combine single nucleotide polymorphisms (SNPs); small insertions and deletions (INDELs); and copy number variations into one seamless analysis. Variant curation tools allow users to review variants, collaboratively build evidence, and securely share it with peers and data-sharing communities. With a range of new features for somatic variant classification, review, and curation, the 5.0 release represents a significant leap forward.

Cartagenia Bench provides direct access to over 100 curated and publicly available databases with information on actionable variants, trials, drugs, and therapy options such as CIViC, COSMIC, N-of-One, OncoMD, and CollabRx.

The software's variant curation tools enable labs to build an internal knowledge base of predictive, prognostic, diagnostic, and functional evidence of previously curated variants. By accessing tumor type-ontology and variant information from the curated and public databases, labs can efficiently implement their variant assessment standard operating procedure to more effectively filter variants and access knowledge based on the tumor's tissue type.

"Translating genomic data into actionable information is challenging,” said Herman Verrelst, Agilent vice president and general manager of the company's Genomics Solutions Division and Clinical Applications Division, “The 5.0 release offers molecular pathology labs access to clinical-grade analysis tools and knowledge — one of the key pain points for the implementation of next-generation sequencing (NGS) in routine oncology testing — to help them efficiently interpret sequencing data of tumor samples and provide actionable information by accessing publicly and curated databases containing peer reviewed evidence on diagnostic, prognostic, and therapeutic variants."

"Since we implemented our routine diagnostic pipeline on Agilent's bench platform, we've appreciated the close collaboration with the team and how they translate our needs into new software versions," said Petra Nederlof, head of Molecular Diagnostics, Netherlands Cancer Institute (Amsterdam).

"We are truly excited by our partnership with Agilent as it extends our reach into the global molecular pathology community," said Dr. Malachi Griffith from McDonnell Genome Institute, Washington University School of Medicine (St. Louis, MO, USA), "With the incorporation of the CIViC knowledge base in Agilent's bench platform, all users will now have direct access to the predictive, prognostic, and diagnostic evidence curated by CIViC domain experts."

Agilent will be showcasing Cartagenia Bench Lab 5.0 and other solutions at the NGS in Molecular Pathology Symposium, November 30-December 2, 2016, at the Netherlands Cancer Institute. "We're excited about co-organizing this event with Agilent," said Dr. Nederlof, "We have a strong agenda of international experts who will share expertise from their clinical diagnostic practices.” The symposium will include tracks on clinical variant assessment and lab reporting, automation, somatic variant classification, NGS panel composition, and data-sharing initiatives.

Related Links:
Agilent Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.